JAK/STAT signal transduction: regulators and implication in hematological malignancies.

Signal transducers and activators of transcription (STATs) comprise a family of several transcription factors that are activated by a variety of cytokines, hormones and growth factors. STATs are activated through tyrosine phosphorylation, mainly by JAK kinases, which lead to their dimerization, nuclear translocation and regulation of target genes expression. Stringent mechanisms of signal attenuation are essential for insuring appropriate, controlled cellular responses. Among them phosphotyrosine phosphatases (SHPs, CD45, PTP1B/TC-PTP), protein inhibitors of activated STATs (PIAS) and suppressors of cytokine signaling (SOCS) inhibit specific and distinct aspects of cytokine signal transduction. SOCS proteins bind through their SH2 domain to phosphotyrosine residues in either cytokine receptors or JAK and thus can suppress cytokine signaling. Many recent findings indicate that SOCS proteins act, in addition, as adaptors that regulate the turnover of certain substrates by interacting with and activating an E3 ubiquitin ligase. Thus, SOCS proteins act as negative regulators of JAK/STAT pathways and may represent tumour suppressor genes. The discovery of oncogenic partner in this signaling pathway, more especially in diverse hematologic malignancies support a prominent role of deregulated pathways in the pathogenesis of diseases. Fusion proteins implicating the JH1 domain of JAK2 (TEL-JAK2, BCR-JAK2), leading to deregulated activity of JAK2, have been described as the result of translocation. Somatic point mutation in JH2 domain of JAK2 (JAK2V617F), leading also to constitutive tyrosine phosphorylation of JAK2 and its downstream effectors was reported in myeloproliferative disorders. Furthermore, silencing of socs-1 and shp-1 expression by gene methylation is observed in some cancer cells.

[1]  J. G. Zhang,et al.  The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Emi,et al.  Suppressor of cytokine signalling‐1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines , 2004, British journal of haematology.

[3]  J. ten Hoeve,et al.  Identification of a Nuclear Stat1 Protein Tyrosine Phosphatase , 2002, Molecular and Cellular Biology.

[4]  M. Makuuchi,et al.  Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. , 2005, Journal of hepatology.

[5]  Kenichi Matsubara,et al.  Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma , 2005, Oncogene.

[6]  R. Weening,et al.  Noonan's syndrome in association with acute leukemia. , 1995, Pediatric hematology and oncology.

[7]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[8]  K. Shuai,et al.  Regulation of gene-activation pathways by PIAS proteins in the immune system , 2005, Nature Reviews Immunology.

[9]  F. Gouilleux,et al.  A Sequence of the CIS Gene Promoter Interacts Preferentially with Two Associated STAT5A Dimers: a Distinct Biochemical Difference between STAT5A and STAT5B , 1998, Molecular and Cellular Biology.

[10]  A. Yoshimura,et al.  Proteasomes Regulate Erythropoietin Receptor and Signal Transducer and Activator of Transcription 5 (STAT5) Activation , 1998, The Journal of Biological Chemistry.

[11]  Kazuhiro Yoshida,et al.  Epigenetic inactivation of SOCS‐1 by CpG island hypermethylation in human gastric carcinoma , 2004, International journal of cancer.

[12]  Mitsutoshi Nakamura,et al.  Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas , 2003, Journal of Human Genetics.

[13]  E. Kremmer,et al.  PIASy-Deficient Mice Display Modest Defects in IFN and Wnt Signaling1 , 2004, The Journal of Immunology.

[14]  K. Vuori,et al.  Negative regulation of FAK signaling by SOCS proteins , 2003, The EMBO journal.

[15]  M. Fujimoto,et al.  IFN Regulatory Factor-1-Mediated Transcriptional Activation of Mouse STAT-Induced STAT Inhibitor-1 Gene Promoter by IFN-γ1 , 2000, The Journal of Immunology.

[16]  J. Burnside,et al.  Computational and functional analysis of the putative SH2 domain in Janus Kinases. , 2000, Biochemical and biophysical research communications.

[17]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[18]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[19]  H. Koeffler,et al.  Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia. , 2003, International journal of oncology.

[20]  Y. Kwong,et al.  SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. , 2004, Blood.

[21]  R. Stocco,et al.  Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. , 1995, Genomics.

[22]  A. Nakao,et al.  Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  C. Litterst,et al.  An LXXLL Motif in the Transactivation Domain of STAT6 Mediates Recruitment of NCoA-1/SRC-1* , 2002, The Journal of Biological Chemistry.

[24]  D. Chang,et al.  Inhibition of Stat1-mediated gene activation by PIAS1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Roberts,et al.  Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways , 1997, Molecular and cellular biology.

[26]  W. Alexander,et al.  The SOCS box: a tale of destruction and degradation. , 2002, Trends in biochemical sciences.

[27]  C. Glass,et al.  Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Bertoglio,et al.  STAT6 and Ets-1 Form a Stable Complex That Modulates Socs-1 Expression by Interleukin-4 in Keratinocytes* , 2004, Journal of Biological Chemistry.

[29]  J. Kutok,et al.  Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation , 2001, Molecular and Cellular Biology.

[30]  R. Berger,et al.  Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. , 2000, Blood.

[31]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[32]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[33]  P. Marynen,et al.  Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. , 1997, Blood.

[34]  J. Johnston,et al.  The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. , 2004, The Biochemical journal.

[35]  U. Lehmann,et al.  Hypermethylation of the suppressor of cytokine signalling‐1 (SOCS‐1) in myelodysplastic syndrome , 2005, British journal of haematology.

[36]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[37]  J. Bromberg.  Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.

[38]  B. Neel,et al.  The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence , 1992, Cell.

[39]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[40]  Martin J S Dyer,et al.  Biallelic deletion within 16p13.13 including SOCS‐1 in Karpas1106P mediastinal B‐cell lymphoma line is associated with delayed degradation of JAK2 protein , 2006, International journal of cancer.

[41]  W. Alexander,et al.  Biological Evidence That SOCS-2 Can Act Either as an Enhancer or Suppressor of Growth Hormone Signaling* , 2002, The Journal of Biological Chemistry.

[42]  F. Sommerer,et al.  SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition , 2005, Oncogene.

[43]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[44]  I. Trowbridge,et al.  CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. , 1994, Annual review of immunology.

[45]  F. Chan,et al.  Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line , 2004, British Journal of Cancer.

[46]  Alexander S. Banks,et al.  SOCS-1 Localizes to the Microtubule Organizing Complex-Associated 20S Proteasome , 2004, Molecular and Cellular Biology.

[47]  T. Arora,et al.  PIASx Is a Transcriptional Co-repressor of Signal Transducer and Activator of Transcription 4* , 2003, Journal of Biological Chemistry.

[48]  J. Darnell,et al.  Two contact regions between Stat1 and CBP/p300 in interferon γ signaling , 1996 .

[49]  O. Silvennoinen,et al.  Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.

[50]  Anastasis Stephanou,et al.  STAT‐1: a novel regulator of apoptosis , 2003, International journal of experimental pathology.

[51]  T. Barth,et al.  [Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line]. , 2004, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[52]  M. Nawijn,et al.  Pim serine/threonine kinases regulate the stability of Socs-1 protein , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Wenjun Cheng,et al.  Activated Signal Transducer and Activator of Transcription (STAT) 3 , 2004, Cancer Research.

[54]  P. Heinrich,et al.  SOCS3 Exerts Its Inhibitory Function on Interleukin-6 Signal Transduction through the SHP2 Recruitment Site of gp130* , 2000, The Journal of Biological Chemistry.

[55]  S. Müller,et al.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Reilly,et al.  Aberrant methylation of the negative regulators RASSFIA, SHP‐1 and SOCS‐1 in myelodysplastic syndromes and acute myeloid leukaemia , 2005, British journal of haematology.

[57]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[58]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[59]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[60]  S. Sukumar,et al.  CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. , 2001, Cancer research.

[61]  A. Frischauf,et al.  IL-4 and IL-13 Induce SOCS-1 Gene Expression in A549 Cells by Three Functional STAT6-Binding Motifs Located Upstream of the Transcription Initiation Site 1 , 2003, The Journal of Immunology.

[62]  Karen Leroy,et al.  Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. , 2004, Blood.

[63]  J. Girault,et al.  Janus Kinases and Focal Adhesion Kinases Play in the 4.1 Band: A Superfamily of Band 4.1 Domains Important for Cell Structure and Signal Transduction , 1998, Molecular medicine.

[64]  Y. Yamashita,et al.  DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome , 2003, British journal of haematology.

[65]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[66]  S. Bohlander,et al.  A BCR–JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia , 2005, Genes, chromosomes & cancer.

[67]  Qian Zhang,et al.  Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma1 , 2002, The Journal of Immunology.

[68]  R Berger,et al.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.

[69]  A. Jegalian,et al.  Regulation of Socs Gene Expression by the Proto-oncoprotein GFI-1B , 2002, The Journal of Biological Chemistry.

[70]  J. Herman,et al.  SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. , 2003, Blood.

[71]  O. Silvennoinen,et al.  The Transcriptional Co-activator Protein p100 Recruits Histone Acetyltransferase Activity to STAT6 and Mediates Interaction between the CREB-binding Protein and STAT6* , 2005, Journal of Biological Chemistry.

[72]  H. F. Barker,et al.  The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. , 2005, Cancer research.

[73]  N. Copeland,et al.  A novel cytokine‐inducible gene CIS encodes an SH2‐containing protein that binds to tyrosine‐phosphorylated interleukin 3 and erythropoietin receptors. , 1995, The EMBO journal.

[74]  Hong Wu,et al.  PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity , 2004, Nature Immunology.

[75]  Sergio Wittlin,et al.  Differential hypermethylation of SOCS genes in ovarian and breast carcinomas , 2004, Oncogene.

[76]  D. Gilliland,et al.  Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation , 2004, Nature Medicine.

[77]  Shu-Wha Lin,et al.  SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia , 2003, Genes, chromosomes & cancer.

[78]  T. Golub,et al.  Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia , 1996, Molecular and cellular biology.

[79]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[80]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[81]  P. Brousset,et al.  The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene , 2005, Oncogene.

[82]  R. Siebert,et al.  Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2 , 2003, International journal of cancer.

[83]  P Jay,et al.  Specific inhibition of Stat3 signal transduction by PIAS3. , 1997, Science.

[84]  M. H. Nguyen,et al.  The tumor suppressor activity of SOCS-1 , 2002, Oncogene.

[85]  K. Okkenhaug,et al.  Socs1 binds to multiple signalling proteins and suppresses Steel factor‐dependent proliferation , 1999, The EMBO journal.

[86]  S. Minoguchi,et al.  The SOCS Box of SOCS-1 Accelerates Ubiquitin-dependent Proteolysis of TEL-JAK2* , 2001, The Journal of Biological Chemistry.

[87]  J. ten Hoeve,et al.  A transcriptional corepressor of Stat1 with an essential LXXLL signature motif , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[88]  J. Herman,et al.  SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity , 2001, Nature Genetics.

[89]  M. Makuuchi,et al.  Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma , 2004, Journal of Gastroenterology.

[90]  D. Hilton,et al.  Regulation of Jak2 through the Ubiquitin-Proteasome Pathway Involves Phosphorylation of Jak2 on Y1007 and Interaction with SOCS-1 , 2002, Molecular and Cellular Biology.

[91]  M. Hermiston,et al.  CD45: a critical regulator of signaling thresholds in immune cells. , 2003, Annual review of immunology.

[92]  K. Bhatia,et al.  Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia , 2004, American journal of hematology.

[93]  Jan-Gowth Chang,et al.  Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia , 2003, British journal of haematology.

[94]  M. Wasik,et al.  STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[95]  M. White,et al.  SOCS-1 and SOCS-3 Block Insulin Signaling by Ubiquitin-mediated Degradation of IRS1 and IRS2* , 2002, The Journal of Biological Chemistry.

[96]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[97]  Y. Kodera,et al.  Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients , 2004, Journal of Gastroenterology.

[98]  R. Hruban,et al.  Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms , 2003, British Journal of Cancer.

[99]  K. Hayashi,et al.  Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. , 2002, Cancer research.

[100]  David P Steensma,et al.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.